AIBOTICS, INC.
AIBT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AIBT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AIBT
Aibotics, Inc. is a pre-revenue biotech company with no revenue, a negative shareholders' equity of -$3.4M, and a cash position of $0.2M as of 2026-06-30, facing substantial doubt about its ability to continue as a going concern.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for AIBOTICS, INC..
Aibotics, Inc. is a pre-revenue biotech company with no revenue, a negative shareholders' equity of -$3.4M, and a cash position of $0.2M as of 2026-06-30, facing substantial doubt about its ability to continue as a going concern.
- No revenue generated to date; net loss of $0.5M for the three months ended March 31, 2026 [sec_mda · as of 2026-06-09].
- Cash and equivalents of $0.2M as of 2026-06-30 [sec].
- Shareholders' equity of -$3.4M and total debt of $1.3M as of 2026-06-30 [sec].
- Working capital deficiency of $4.7M as of March 31, 2026 [sec_mda · as of 2026-06-09].
- Accumulated deficit of $12.4M as of September 30, 2025 [sec_mda · as of 2025-11-19].
What works
- The company has maintained some cash reserves, with cash increasing from $230,470 (Sep 2025) to $288,858 (Mar 2026) primarily through financing activities [sec_mda · as of 2025-11-19][sec_mda · as of 2026-06-09].
- Net loss decreased from $591,397 (Q1 2025) to $418,105 (Q1 2026), indicating some cost control [sec_mda · as of 2026-06-09].
What to weigh
- No revenue has been generated since inception, with zero revenue reported for the year ended December 31, 2024 [sec_mda · as of 2025-04-11].
- Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and negative cash flows [sec_mda · as of 2024-08-19].
- Working capital deficiency of $4.7M as of March 31, 2026, with current liabilities far exceeding current assets [sec_mda · as of 2026-06-09].
- Total debt of $1.3M as of 2026-06-30, with undiscounted obligations of approximately $1.3M due within one year [sec][sec_mda · as of 2026-06-09].
From the filings
Quoted directly from source documents.
No revenue generated to date
“To date, the Company has generated no revenues, experienced negative operating cash flows and has incurred operating losses since inception.”
SEC MD&A · August 19, 2024
Net loss for Q1 2026
“For the three months ended March 31, 2026 and 2025 we had a net loss of $418,105 and $591,397, respectively.”
SEC MD&A · June 9, 2026
Working capital deficiency as of March 31, 2026
“As of March 31, 2026, we had a working capital deficiency of $4,720,284”
SEC MD&A · June 9, 2026
Substantial doubt about going concern
“These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of time within one year after that date”
SEC MD&A · August 19, 2024
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern due to no revenue, negative cash flows, and working capital deficiency [sec_mda · as of 2024-08-19].
- Liquidity risk — Cash of only $0.2M with $1.3M debt due within one year; working capital deficit of $4.7M [sec][sec_mda · as of 2026-06-09].
- No revenue generation — Company has never generated revenue and relies on debt/equity financing to fund operations [sec_mda · as of 2024-08-19].
- Accumulated deficit — Accumulated deficit of $12.4M as of September 30, 2025, reflecting persistent losses [sec_mda · as of 2025-11-19].
What to watch
- Ability to raise additional financing to fund operations and debt obligations [sec_mda · as of 2026-06-09].
- Progress toward generating revenue or achieving a milestone that could improve liquidity [sec_mda · as of 2024-08-19].
- Any updates on the company's business plan or potential partnerships that could alter its financial trajectory [sec_mda · as of 2026-06-09].
Sources: SEC MD&A · Generated August 21, 2026 · How we verify sources →
Run AIBOTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AIBOTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
15.7 months
OCF -$47K · Net income -$537K
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for AIBOTICS, INC.?
Aibotics, Inc. is a pre-revenue biotech company with no revenue, a negative shareholders' equity of -$3.4M, and a cash position of $0.2M as of 2026-06-30, facing substantial doubt about its ability to continue as a going concern.
Who is the CEO of AIBOTICS, INC.?
Mr. Benjamin Kaplan is the chief executive officer of AIBOTICS, INC. (AIBT).
Where is AIBOTICS, INC. headquartered?
AIBOTICS, INC. (AIBT) is headquartered in Miami, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.